invoX is a wholly owned subsidiary of Sino Biopharmaceutical Limited, a global top 50 pharmaceutical company with more than 24,000 employees. Headquartered in London, invoX is an expanding international biopharmaceutical platform. Through multiple acquisitions and investments, invoX is to create a scalable platform to build a portfolio of promising clinical and pre-clinical stage drug candidates, which we believe will improve people’s lives by creating access to innovative medicine across some of our key therapeutic areas including oncology and respiratory. Our core team is made up of a multicultural international group of highly experienced individuals with life sciences and technology-centred backgrounds, all with a mutual passion and ambition for creating something different. Mission: invoX is to be a globally recognized, fully integrated pharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs. Check out our recent acquisitions and investments: Soft Mist Inhalation(SMI) Platform: https://www.softhale.com/ mRNA Delivery Platform: https://www.phiontx.co.uk/